JUser: :_load: Unable to load user with ID: 42

JUser: :_load: Unable to load user with ID: 50

CoreRx on Facebook CoreRx on Twitter CoreRx on LinkedIn
Sunday, 19 June 2011 00:00

CoreRx Named to Tampa’s 2011 Fast 50

CoreRx, fast becoming a world-recognized leader in early drug contract development, was announced today as one of Tampa Bay’s Fast 50  companies. The Tampa Bay Business Journal’s Fast 50 is a list of the  fastest growing privately held companies in Tampa Bay over a span of  three years. Last year, CoreRx was recognized as the  6th fastest growing company in the Tampa Bay region.

“We feel honored to be part of such a reputable list of companies,”  stated Dr. Todd R. Daviau, President and CEO of CoreRx. “From every  single dosage form we develop to every minute we save our customers, we  are always aiming to be the best company we can possibly be. Our  commitment to our customers is reflected in our steady growth over the  last five years.”

CoreRx is a contract research organization providing formulation   development, preformulation, analytical, and clinical trial   manufacturing to American and European companies since 2006. The company   is renowned for reliably expediting early development activities to   speed potential drugs to clinical trials while applying stage-specific   scientific knowledge and experience. CoreRx’s unique corporate structure   creates project teams that work intensively with each client, bringing   an extension of their own organization into CoreRx.

As a fully cGMP contract facility, CoreRx provides formulation   development, analytical, and clinical material resources, utilizing a   variety of multi-layer tablet equipment for combination products. CoreRx   also offers development and manufacture of multi-particulate   combination drug products.   Whether your need is for multiple tablets   in a capsule, pellets, granules, nano-particles, co-processed spray   dried powders or multiple powders in capsules, CoreRx has you covered.

About CoreRx:
Keep on top of new developments and throughout the  drug development industry by following us on Twitter: www.twitter.com/CoreRx.

Last modified on Tuesday, 14 February 2012 21:30

source logos